These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 17971711)

  • 1. Persistent intrathecal immune activation in HIV-1-infected individuals on antiretroviral therapy.
    Yilmaz A; Price RW; Spudich S; Fuchs D; Hagberg L; Gisslén M
    J Acquir Immune Defic Syndr; 2008 Feb; 47(2):168-73. PubMed ID: 17971711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low levels of HIV-1 RNA detected in the cerebrospinal fluid after up to 10 years of suppressive therapy are associated with local immune activation.
    Dahl V; Peterson J; Fuchs D; Gisslen M; Palmer S; Price RW
    AIDS; 2014 Sep; 28(15):2251-8. PubMed ID: 25022595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiretroviral treatment effect on immune activation reduces cerebrospinal fluid HIV-1 infection.
    Sinclair E; Ronquillo R; Lollo N; Deeks SG; Hunt P; Yiannoutsos CT; Spudich S; Price RW
    J Acquir Immune Defic Syndr; 2008 Apr; 47(5):544-52. PubMed ID: 18362693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment.
    Edén A; Fuchs D; Hagberg L; Nilsson S; Spudich S; Svennerholm B; Price RW; Gisslén M
    J Infect Dis; 2010 Dec; 202(12):1819-25. PubMed ID: 21050119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cerebrospinal fluid HIV-1 RNA, intrathecal immunoactivation, and drug concentrations after treatment with a combination of saquinavir, nelfinavir, and two nucleoside analogues: the M61022 study.
    Yilmaz A; Fuchs D; Hagberg L; Nillroth U; Ståhle L; Svensson JO; Gisslén M
    BMC Infect Dis; 2006 Mar; 6():63. PubMed ID: 16566834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cerebrospinal fluid viral load in HIV-1-infected patients without antiretroviral treatment: a longitudinal study.
    Gisslén M; Hagberg L; Fuchs D; Norkrans G; Svennerholm B
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Apr; 17(4):291-5. PubMed ID: 9525428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cerebrospinal fluid viral load, intrathecal immunoactivation, and cerebrospinal fluid monocytic cell count in HIV-1 infection.
    Gisslén M; Fuchs D; Svennerholm B; Hagberg L
    J Acquir Immune Defic Syndr; 1999 Aug; 21(4):271-6. PubMed ID: 10428104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrospinal fluid neopterin decay characteristics after initiation of antiretroviral therapy.
    Yilmaz A; Yiannoutsos CT; Fuchs D; Price RW; Crozier K; Hagberg L; Spudich S; Gisslén M
    J Neuroinflammation; 2013 May; 10():62. PubMed ID: 23664008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebrospinal fluid viral load and neopterin in HIV-positive patients with undetectable viraemia.
    Motta I; Allice T; Romito A; Ferrara M; Ecclesia S; Imperiale D; Ghisetti V; Di Perri G; Bonora S; Calcagno A
    Antivir Ther; 2017; 22(6):539-543. PubMed ID: 28198350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cerebrospinal fluid and plasma HIV-1 RNA levels and lopinavir concentrations following lopinavir/ritonavir regimen.
    Yilmaz A; Ståhle L; Hagberg L; Svennerholm B; Fuchs D; Gisslén M
    Scand J Infect Dis; 2004; 36(11-12):823-8. PubMed ID: 15764168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebrospinal fluid viral load, virus isolation, and intrathecal immunoactivation in HIV type 2 infection.
    Arvidson N; Gisslén M; Albert J; Brandin E; Svennerholm B; Fuchs D; Hagberg L
    AIDS Res Hum Retroviruses; 2004 Jul; 20(7):711-5. PubMed ID: 15307916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment intensification has no effect on the HIV-1 central nervous system infection in patients on suppressive antiretroviral therapy.
    Yilmaz A; Verhofstede C; D'Avolio A; Watson V; Hagberg L; Fuchs D; Svennerholm B; Gisslén M
    J Acquir Immune Defic Syndr; 2010 Dec; 55(5):590-6. PubMed ID: 20847699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy.
    Canestri A; Lescure FX; Jaureguiberry S; Moulignier A; Amiel C; Marcelin AG; Peytavin G; Tubiana R; Pialoux G; Katlama C
    Clin Infect Dis; 2010 Mar; 50(5):773-8. PubMed ID: 20100092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuing intrathecal immunoactivation despite two years of effective antiretroviral therapy against HIV-1 infection.
    Abdulle S; Hagberg L; Svennerholm B; Fuchs D; Gisslén M
    AIDS; 2002 Nov; 16(16):2145-9. PubMed ID: 12409735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discordant CSF/plasma HIV-1 RNA in individuals on virologically suppressive antiretroviral therapy in Western India.
    Dravid AN; Natrajan K; Kulkarni MM; Saraf CK; Mahajan US; Kore SD; Rathod NM; Mahajan US; Wadia RS
    Medicine (Baltimore); 2018 Feb; 97(8):e9969. PubMed ID: 29465595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of immunologic restoration and virologic response in plasma, tonsillar tissue, and cerebrospinal fluid in HIV-1-infected patients treated with double versus triple antiretroviral therapy in very early stages: The Spanish EARTH-2 Study. Early Anti-Retroviral Therapy Study.
    García F; Alonso MM; Romeu J; Knobel H; Arrizabalaga J; Ferrer E; Dalmau D; Ruiz I; Vidal F; Frances A; Segura F; Gomez-Sirvent JL; Cruceta A; Clotet B; Pumarola T; Gallart T; O'Brien WA; Miró JM; Gatell JM
    J Acquir Immune Defic Syndr; 2000 Sep; 25(1):26-35. PubMed ID: 11064501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased blood-brain barrier permeability in neuro-asymptomatic HIV-1-infected individuals--correlation with cerebrospinal fluid HIV-1 RNA and neopterin levels.
    Andersson LM; Hagberg L; Fuchs D; Svennerholm B; Gisslén M
    J Neurovirol; 2001 Dec; 7(6):542-7. PubMed ID: 11704886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Asymptomatic Cerebrospinal Fluid HIV-1 Viral Blips and Viral Escape During Antiretroviral Therapy: A Longitudinal Study.
    Edén A; Nilsson S; Hagberg L; Fuchs D; Zetterberg H; Svennerholm B; Gisslén M
    J Infect Dis; 2016 Dec; 214(12):1822-1825. PubMed ID: 27683820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Persistent central nervous system immune activation following more than 10 years of effective HIV antiretroviral treatment.
    Ulfhammer G; Edén A; Mellgren Å; Fuchs D; Zetterberg H; Hagberg L; Nilsson S; Yilmaz A; Gisslén M
    AIDS; 2018 Sep; 32(15):2171-2178. PubMed ID: 30005007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral load.
    Peluso MJ; Ferretti F; Peterson J; Lee E; Fuchs D; Boschini A; Gisslén M; Angoff N; Price RW; Cinque P; Spudich S
    AIDS; 2012 Sep; 26(14):1765-74. PubMed ID: 22614889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.